A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

May 17, 2021

Study Completion Date

May 31, 2021

Conditions
Ulcerative Colitis
Interventions
DRUG

GLPG3970

GLPG3970 powder and solvent for oral solution reconstituted prior to use.

DRUG

Placebo

Placebo powder and solvent for oral solution reconstituted prior to use.

Trial Locations (15)

2025

ARENSIA Exploratory Medicine Phase I Unit, Chisinau

21018

M.I. Pyrogov VRCH Dept of Gastroenterology M.I. Pyrogov VNMU, Vinnytsia

21029

CCH #1 Vinnytsia M.I. Pyrogov NMU Ch of Propaedeutics of IM, Vinnytsia

SRI of Invalid Rehabilitation (EST Complex) of Vinnytsia M.I.Pyrogov NMU MOHU, Vinnytsia

49005

I.I.Mechnykov Dnipropetrovsk Regional Clinical Hospital, Dnipro

61037

CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2, Kharkiv

61124

CHI Kharkiv City Clinical Hospital #13, Kharkiv

73000

Communal Nonprofit Enterprise Kherson City Clinical Hospital n.a. Afanasii and Olga Tropini, Kherson

76000

Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk

0112

Arensia Exploratory Medicine LLC, Tbilisi

31-513

Centrum Medyczne PROMED, Krakow

81-756

Endoskopia Sp. z o.o., Sopot

22-400

ETG Zamosc, Zamość

01135

"Medical Center Harmoniya Krasy", Kyiv

02091

Med Center 'Ok!Clinic+' of International Institute of Clinical Trials LLC, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT04577794 - A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis | Biotech Hunter | Biotech Hunter